Table1. Main Characteristics of Included Studies .

Authors	Country	Population	Gender	Medications/ control group	Dosage of intervention	Duration of intervention	Mean age (intervention/ control groups )
Cambron et al., (2019) [21][A1]	Belgium	PPMS/SPMS	F	Fluoxetine/ Placebo	20 mg/day	108 weeks	54±6.11, 51.2±7.64
De Angelis et al., (2020) [20]	UK	SPMS	M/F	Fluoxetine/ Placebo	20 mg/day	96 weeks	54.83±7.1, 54.89±7.16
Ehde et al., (2008) [19]	USA	MS and MDD	M/F	Paroxetine/ Placebo	10 mg/day for 1 week and 20-40 mg/day after 1 week	12 weeks	≥18 years old
Hassan et al., (2021) [12]	Egypt	RRMS	M/F	SSRI/ rTMS	NR	6 weeks	31.2±4.7, 29.3±3.7
Mohr et al., (a) (2001) [17]	USA	MS and MDD	M/F	Sertraline/ CBT	88.75 mg/day	16 weeks	43.9±10, 43.9±10
Mohr et al., (b) (2001) [17]	USA	MS and MDD	M/F	Sertraline/ SEG	88.75 mg/day	16 weeks	43.9±10, 43.9±10
Mostert et al., (2008) [15]	Netherlands	RRMS	M/F	Fluoxetine/ Placebo	20 mg/day	24weeks	41±10, 38±9
Mostert et al., (2013) [18]	Netherlands	PPMS/SPMS	M/F	Fluoxetine/ Placebo	40 mg/day	104 weeks	49.7±9.2, 47.5±7.6

^*Abbreviation: F: Female; M: male; PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive multiple sclerosis; MS: multiple sclerosis; MDD: major depressive disorder; RRMS: relapsing-remitting multiple sclerosis; SSRIs: selective serotonin reuptake inhibitors; rTMS: repetitive transcranial magnetic stimulation; CBT: cognitive behavioral therapy; SEG: supportive-expressive group therapy; NR: not reporting.